Center of excellence for particle size reduction services

Our Monteggio (CH) site serves as the European Center of Excellence for particle engineering, and provides particle size control expertise through micronization technologies. The Monteggio site - and its US equivalent in Quakertown, PA - is an integral component of our drug product design, development and manufacturing services network.

With 19 production suites and 37 cGMP jet and pin mills, the site is well equipped to support your compound at any point of the product lifecycle. We provide micronization services from a few grams to tons of APIs. Dedicated areas for steroids, cryogenic capabilities for elastic / semi-solid milling, and isolation for highly potent active pharmaceutical ingredients (HPAPIs) are available. Our skilled team of engineers and technical staff evaluate your compound carefully and adapt equipment and processing parameters to address dissolution rate, stability, flowability and other performance issues required to meet target product profiles for oral solid, inhaled and other drug delivery routes.

years experience in particle engineering
actives handled every year
of different active ingredient micronized

Particle engineering for HPAPI

At our Monteggio (CH) site, we evaluate every compound through our HS&E department and then assign a suitable containment system solution according to the OEL. Our facility has a number of rigid and flexible isolators to match the containment requirements of your compounds at any stage of product development. A range of mechanical and jet milling capabilities are available with isolation designed to meet containment levels down to 1 µg/m³ at scales from 2-100 kg batch sizes.  

Proven capabilities

We have premier capabilities and capacity in particle size reduction services through its Monteggio (CH) and Quakertown (PA, US) sites. These complementary sites share best practices in process optimization, mill design and operations. Regulatory registrations / inspections across the two sites include: FDA; SwissMedic; Japan Ministry of Health, Labor and Welfare; Korea FDA, and Australian Deptartment of Health.

Related content

HPAPI Product Handling
We have specific capabilities, infrastructure and expertise in handling highly potent API (HPAPI) compounds.
SimpliFiH™ Solutions: First-in-Human Services
We can provide integrated drug substance and drug product services for preclinical studies and phase I clinical trials.
Micronization and Jet milling
Particle size reduction is increasingly utilized to address a range of formulation issues facing oral solid and inhaled dosage forms. Stability, flowability, dissolution rate and bioavailability are critical performance parameters impacted by particle size distribution. Micronization through jet milling is a core strength of Lonza with unparalleled expertise, track record and capacity in place to meet these challenges.
BA Enhancement
The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing drug solubility and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and delivery challenges. Our end-to-end solutions incorporate full capabilities in bringing a compound from concept to commercialization, thereby minimizing program complexity, timelines and risk.
Particle Engineering
Particle engineering is increasingly required to prepare active pharmaceutical ingredients for effective drug product formulation. We provide customized and fit-for-purpose particle engineering to our customers as part of our integrated product development services.